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Abstract
Two decades after their discovery, stapled peptide methodologies have evolved to a
point where they can be used with confidence to generate therapeutic leads.
Research groups across the world are testing innovative methodologies for their
design, with dozens of publications released every month. A number of stapled pep-
tide drug candidates have recently entered clinical trials. In this review, we provide
an overview of successful methods for their construction, highlight trends in the
deposited crystal structures of stapled peptide complexed to their targets and discuss
properties that contribute towards improved pharmacological profiles.
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1 | INTRODUCTION
Despite heavy investment in the early 21st century, a number of
challenges have stalled the development of marketable peptide
therapeutic drugs. As a consequence, between 2003 and 2019 only
13 synthetic peptide drugs reached the European market.[1] But
with 140 peptides in clinical development in 2019,[2] interest in this
class of therapeutics is clearly growing and constrained peptide
technologies have attracted attention from larger pharmaceutical
companies as well as academic laboratories and smaller start-ups.[3]
Short peptides with natural aminoacids usually have poor drug-like
properties since they frequently have high conformational variabil-
ity, low cell penetration, and undergo rapid proteolysis; while longer
peptides can be challenging both to produce and deliver in cells.
Some of the earliest peptide drugs developed over 50 years ago,
were natural hormones such as insulin,[4] erythropoietin,[5]
oxytocin,[6] secretin[7] and calcitonin,[8] which all have compara-
tively high molecular masses (3-7 kDa). However, shorter peptides
were also marketed during the same period; including
vasopressin,[9] a natural 10-mer peptide hormone. Notably the first
seven FDA-approved peptidic drugs (Insulin, Adrenocorticotropic
hormone, Calcitonin, Oxytocin, Vasopressin, Octreotide and
Leuprorelin)[10] all had a stabilised, or constrained, secondary struc-
ture, which is linked to improved resistance to proteolysis. Thus,
stabilisation of secondary structure, be it through the introduction
of non-peptidic fragments, backbone modifications, or unnatural
amino acids to the sequence has been a prominent feature of pep-
tide drug development since the 1990s.
Stapled peptides, whereby cross-linking of two or more side-
chains is carried out via chemical synthesis, generally have a more
compact structure, enhanced cell penetration, and are more resistant
to proteolysis.[11–13] Moreover, their metabolites are relatively
safe,[14] and recent studies suggest that stapled peptides offer an
advantage over traditional drugs by averting the development of drug
resistance.[11,15] Hence stapled peptides have predictably sparked a
growing interest from the scientific community since the early 2000s
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and have emerged as a potential new class of drugs. A 2019 review
by Ali et al. found 78 stapled peptides where structural information
has been submitted to the protein databank (PDB),[16] of which 55 also
had binding affinity reported. In parallel, the chemistry landscape for
stapled peptides is continuously diversifying with a dozen “novel”
linker chemistries reported in publications in 2019.[17–23] In some
instances, only very subtle differences in the staple chemistry, or ste-
reochemistry, trigger a significant change in the binding affinity, the
pharmaceutical profile of the peptide, or give added
functionality.[21,24–29] Despite multiple publications and reviews
describing reliable methods for the synthesis of stapled peptides[30–35]
35] and the commercialisation of the most common unnatural amino
acids, their synthesis remains costly and until a few years ago, non-
automated. Consequently, the synthesis and screening of stapled pep-
tides have usually been restricted to a few dozen peptides, limiting
access to extensive libraries.
Stabilized peptide scaffolds sit at the interface of biologics and
small-molecule drugs, and guidance for their development can be
found in both fields. In this review, we focus on the successful
approaches that have been published for the design of stapled pep-
tides that inhibit specific protein-protein interactions (PPIs), and do
not cover the design of stapled peptides that act as antimicrobial pep-
tides (AMPs). Since many stapled peptides are designed to inhibit
intracellular PPIs, they necessarily share common features with
another class of peptide therapeutic, the cell-penetrating peptides
(CPPs).[15,18,36-40] We cover some of the notable strategies that have
been used to optimise the pharmacokinetic properties of stapled pep-
tides sequences, enhance their activity and reduce their proteolysis.
But whilst we have focussed this review on these enhancements, not-
ing the expanding interest of pharmaceutical companies for novel
peptides,[41] in some cases more “classical approaches” might provide
a better alternative to stapling.[42,43] Rather than highlighting solely
standard PPI targets (e.g., p53-MDM2/MDMX,[44–48] BCL9/
β-catenin,[49] BCL-2[BAX]/BCL-XL,[50] HIV gp41/10E8 antibody,[51]
LEDGF-p75/HIV-IN)[52], we have included a broad range of examples
from the very recent literature to show how widely peptide stapling is
being adopted.
2 | SECTION 1: DEFINING THE PRIMARY
SEQUENCE
Cell signalling is achieved principally through a cascade of protein-
protein interactions that assemble functionally related proteins into
complexes, activating signal transduction pathways. The protein interac-
tion network of an organism, or interactome, generally gives a better
indication of its biological complexity than its genome. In 2017, Hutlin
et al.[53] estimated the number of candidate interactions in the human
interactome as 56 000; specificity at the binding interface is thus essen-
tial to ensure cell functionality. As for natural peptides, the specificity of
stapled peptides is largely ensured by the choice of the amino acids
interfacing with the target protein. The synthetic landscape is vast: using
the 20 natural amino acids to build peptides of up to five residues gives
over 3 million possible sequences. The synthesis of stapled peptides is
more challenging than linear peptides, as they often contain unnatural
amino acid (uAA) residues that are not biosynthesized by bacteria, and
can be costly to prepare. In this section, we have analysed recent suc-
cesses in the design of stapled peptides to identify specific techniques
used for their primary sequence optimisation (Figure 1).
2.1 | Natural peptide interaction sequences
Starting from a lead peptide with poor pharmacokinetics and improv-
ing its properties by using stapling techniques is the most obvious
route to advance the development of peptide therapeutics. Multiple
successful examples have been reported in which stapling has been
achieved across a variety of secondary structures such as helical pep-
tides, beta-hairpins, and “extended” peptides.
In 2017, Wu et al.[56] investigated the cell penetrant helical peptide,
melittin. Melittin is a naturally occurring peptide from honeybee venom
that has been found to inhibit the proliferation of hepatocellular carci-
noma (HCC) cancerous cells. Wu et al. prepared a library of stapled pep-
tides by truncation and optimisation of the staple position and length,
using Verdine's ring-closing metathesis method for all-hydrocarbon sta-
ple production.[57] The stapled peptides only differed in the length of the
F IGURE 1 Approaches to defining the primary sequence of stapled peptides. A, Starting from a natural peptide interaction sequence. B,
Excising a helical fragment from a protein-protein interface. C, Developing stapled peptide sequences using screening. D, Computational design of
stapled peptide primary sequences
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truncated peptide, the residues replaced by the staple, and the length of
the staple linker. Some of the stapled peptides exhibit enhanced binding
affinity and significantly improved resistance to proteolysis over the par-
ent peptide. The enhanced helicity of a stapled peptide in solution often
promotes its activity; stapled peptides based on the sequence of helical,
estrogen receptor (ER) coactivator peptides, show a marked increase in
helicity and enhanced Kd relative to the initial peptide while retaining an
almost identical binding mode.[58] The HIF-1α/p300 PPI plays a key role
in tumour metabolism. The HIF-1α peptide is a 40-mer containing three
alpha-helical segments each of which binds p300 at a specific site. By
focusing on the largest helical segment, and using a dibromomaleimide
stapling strategy, a competitive binder of the HIF-1α peptide with
increased helicity in the bound state was reported (Figure 2A).[54]
Nonhelical stapled peptides have also been developed in recent
papers targeting nuclear PPIs. Wiedmann et al.[55] used peptides based
on an HNF1β NLS sequence developed in the 1990s by Lin et al.[59] and
“double click” CuACC staple chemistry,[60,61,62] to produce a series of
constrained extended stapled peptides (Figure 2B). Initial bis-triazole sta-
pled peptides had reduced binding affinity for their importin protein tar-
get relative to the peptide lead. After further optimisation of the linker
length, a stapled peptide with an equivalent low micromolar Kd was gen-
erated. Crucially, cell penetration was only observed for the stapled pep-
tide. McGrath et al. have also designed a constrained peptide that binds
to the WDR domain of Transducin-like Enhancer (TLE). The design was
based on a peptide derived from a transcription factor binding partner.[63]
Stapling this short peptide was achieved by linking the indole moiety of
the N-terminal tryptophan to the C-terminal proline via ring-closing
metathesis. X-ray analysis showed that the binding mode was almost
identical to that of the initial peptide with an approximately 6-fold higher
affinity of the stapled peptide over its acyclic counterpart.[59]
2.2 | Excision of a helical fragment from a protein-
protein interface
Frequently structural data for a PPI implicated in a disease is available,
but no peptide binders have been reported If the binding interface
includes one short contiguous protein segment, this becomes a conve-
nient starting point for the development of a therapeutic peptide. If
the secondary structure of the interacting protein segment promotes
the positioning of the PPI interacting residues, peptide stapling is most
likely to reproduce the native contacts. Indeed, McWhinnie et al. have
reported three hydrocarbon-stapled peptide series which reproduce
the secondary structure of the native protein they were extracted
from (αSyn, CKS1 and CK1α) with high fidelity, whereas the unstapled
natural sequences displayed almost no secondary structure content
(Figure 3A).[64] Similarly, Wang et al. have isolated a minimum helical
motif from the coiled-coil region identified in the crystal structure of
the respiratory syncytial virus fusion (RSV-F) protein,[65] and then
enhanced the helicity of this initial peptide sequence using computa-
tional mutagenesis and all-hydrocarbon peptide stapling, achieving a
corresponding 2-fold improvement in binding affinity.
Successful examples of a peptide excision strategy applied to the
generation of all-hydrocarbon stapled peptides include: stapled pep-
tides which block the helix-helix interfaces found in the coiled-coil
region of the gp41 protein with potent anti-viral activity against HIV-
1;[67] stapled peptides which mimic the junction domain of Plasmodium
falciparum calcium-dependent protein kinase 1 (PfCDPK1; Figure 3B) to
disrupt J-domain binding and provide allosteric inhibition of PfCDPK1
activity, blocking malarial parasite development;[66] stapled peptides
extracted from the dimerization interface of bone morphogenetic
protein-2 (BMP-2) which is a possible target for bone repair thera-
pies;[68] stapled peptides which target the nuclear transcription factor
NF-Y, a therapeutic target implicated in various diseases such as can-
cers and neurodegeneration.[69] Clearly, the success of these strategies
has relied on the availability of crystallographic data and amino acid
building blocks to readily synthesize stapled peptide sequences.
2.3 | Stapled peptide sequences from biological
screening
Until very recently, many popular biological approaches used for the
development of peptide therapeutic leads (e.g., phage display,[70]
F IGURE 2 Peptide conformations constrained by stapling. A, Crystal structure of HIF-1α (blue) binding to p300 (green); A1, Model of a
stapled peptide (blue) derived from HIF-1α binding to p300 (green) reproducing similar contacts. Reproduced from Chem. Eur. J. 2020, 26,
7638-7646, under Creative Commons Licence CC-BY. B, Crystal structure of an extended stapled peptide (orange) derived from the HNF1β NLS
peptide which binds to mImportin α1. Reproduced from Angew. Chem. Int. Ed. 2017, 56, 524-529, under Creative Commons Licence CC-BY
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ribosome display,[71] mRNA-display,[72] bacterial or yeast surface dis-
play)[73] could not be applied to the development of stapled peptides
due to the need to incorporate unnatural amino acids, and stapling
reaction protocols harmful to bacteria or phages. Instead, such screen-
ing methodologies are used to identify initial peptide leads that are then
optimised into stapled variants. To illustrate, Achek et al. discovered
the first peptide inhibitor of TLR4, a key target for the treatment of
rheumatoid arthritis, using phage display techniques and lactam stapling
which increased the helicity of the initial peptide and improved its IC50
2-fold over its unstapled variant.[74] Developments in stapling method-
ologies now allow biological screening to be applied to stapled pep-
tides, where the staple is introduced through cysteine alkylation. In this
instance, no uAA incorporation is required, and the cross-linking reac-
tion can be conducted under mild, dilute conditions that are not delete-
rious to phages. Using a phage library based on the axin α-helix
(Figure 4A), Diderich et al. were able to generate a cysteine-stapled
peptide PPI inhibitor for β-catenin which showed nanomolar activity in
a fluorescence polarization competition assay.[75] Using the same
approach with biphenyl linkers, Anananuchatkul et al. produced micro-
molar binders of Galectin-3.[76] The cysteine alkylation approach has
been extended to the incorporation of α-methyl substituted cysteine
using a strategy based on the mRNA display of peptides (Figure 4B).
This uAA has been shown to increase the helical propensity of the
cysteine-stapled peptide, giving similar properties to related all-
hydrocarbon stapled peptides with α-methyl substitution.[77] Since
mRNA display can create libraries that are several orders of magnitude
larger than on-bead or phage display libraries, this could be a very pow-
erful strategy for the generation of new stapled peptide leads.
2.4 | Computational design of stapled peptide
sequences
Analysis of structures of protein-peptide complexes derived from X-
ray diffracted crystals, NMR measurements or molecular dynamics
(MD) simulations is another effective approach to design of stapled
peptide sequences (Figure 1D). The most straightforward analyses
rely on interactive 3D visualisation of structures using popular molec-
ular graphics software such as Pymol.[78] The position and spacing of
hydrogen bonds and hydrophobic contacts at a binding interface allow
key residues to be inferred. When multiple structures of related pep-
tides are available it may be possible to deduce conformational
changes that occur upon binding linear sequences to direct staple
optimisation.[79,80] A complementary computational approach to this
structure-based design of stapled peptides involves extracting func-
tionally significant patterns from the sequences of naturally occurring
peptides and re-using these leads to design de novo peptides. This
type of bioinformatics approach requires large databases of peptides
with known activity and consequently has not yet played a major role
in stapled peptide design, owing to the comparatively small number of
such datasets in the literature. Howerer, fast and reliable methods
such as AGADIR[81] could potentially be used prior to the introduction
of staples to enhance the overall propensity of a peptide sequence to
fold into an α-helix.[82] The reader is directed to an extended review
of AMP databases and data mining by Porto et al. for further
details.[83]
MD simulations enhance structure-based visualisation methods
for peptide design by providing information about molecular
F IGURE 3 Excision strategies in the design of stapled peptides. A, NMR Structures of three stapled peptides derived from (a) αSyn (purple),
(b) Cks1 (orange) and (c) CK1α (blue) aligned with their initial protein segment (green). PDB codes 1XQ8, 2AST and 1CK1_A. Reproduced with
permission from Chem. Eur. J. 2018, 24, 2094-2097, Copyright 2018 John Wiley and Sons. B, Design of a stapled peptide (orange) from the
excision of the junction domain of Plasmodium falciparum Calcium-Dependent Protein Kinase 1 (orange) in a catalytically inactive state.
Calmodulin-like domain and kinase domain shown in blue and gray respectively. PDB code 3KU2. Reproduced with permission from ACS Infect.
Dis. 2019, 5, 506-514, Copyright 2019 American Chemical Society
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flexibility, and estimates of binding energetics. MD simulations may
be used on their own, but also in conjunction with other computa-
tional methods, such as free energy calculations, metadynamics, ste-
ered MD, parallel MD and other methods which overcome limitations
inherent to Boltzmann sampling.[84–89] In theory, any MD method for
the design of peptides could be adapted to stapled peptides. How-
ever, a major limitation currently is the availability of high quality
parameter sets to model the energetics of unnatural amino acids. To
date, only a few MD methods have been applied to stapled peptides.
Fragment-based approaches, such as those applied to the develop-
ment of small molecule binders and to predicting binding pockets,
have been successfully transposed to the design of stapled peptides
by Tan et al. who used a fragment screen on MDM2 to optimise the
placement of both aromatic and staple residues in their peptide lead
(Figure 5A).[90] The MELD accelerated sampling technique, which
uses a Hamiltonian and temperature replica exchange approach,
accurately predicts binding poses of stapled peptides where key
interactions are known, and also predicts the binding energy of pep-
tides (Figure 5B).[91,92] Free energy perturbations (FEP) can be used
to improve a given sequence; typically a virtual alanine scan is con-
ducted and the free energy is computed to measure the effect of
changes,[93] or to enhance the binding properties of the peptide.[94]
Despite advances in FEP methods for macrocycles,[95,96] application
of this method to stapled peptides could suffer from complications
if the mutations occurred at the staple residues. As an example, Val-
iente et al. describe the use of FEP methods for sequence selection,
combined with umbrella sampling calculations to estimate binding
free energies of the modelled stapled-peptides to the target recep-
tor BCLXL.
[97] The binding energy between a peptide and protein
can also be estimated with the Molecular Mechanics/Poisson
Boltzmann Surface Area (MM/PBSA) or Molecular Mechanics/Gen-
eralized Born Surface Area (MM/GBSA) methods.[98] In these
methods, molecular dynamics simulations of the receptor-ligand
complex in explicit, or implicit, solvent are run to calculate the free
energy of solvation of the complex. A few examples of the applica-
tion of MM/GBSA to stapled peptides have been reported, which
helped understand the role of hydration and flexibility in stapled-
peptide binding.[46,99–101]
Using docking algorithms to predict specific binding poses for
large ligands and peptides is more challenging than for typical drug-
like small molecules. First, the PPI binding surface is usually larger and
lacking in distinct features, with more hydrophobic contacts than
binding pockets for small molecules.[94] Second, the conformational
landscape of peptides is broader due to the large number of backbone
and side-chain torsional degrees of freedoms that typically exceeds
the sampling capabilities of most docking algorithms. Several methods
have been designed to overcome the difficulties arising from docking
peptides, such as allowing side-chain flexibility, or rearrangement, dur-
ing docking.[87] In practice, the more effective docking protocols for
peptides are based on protein docking algorithms rather than small
molecule docking algorithms. Applications of docking algorithms
include publications by Ciemny et al. who successfully modelled the
flexible regions during p53 peptide binding to the MDM2 protein
receptor,[102] using the CABS-dock method which accommodates
large-scale structural rearrangements (Figure 5C);[103] and Tiwari et al.
who successfully modelled docking of the p53-activating peptide
ATSP-7041 to albumin,[46] using the protein-protein docking program
ATTRACT.[104]
F IGURE 4 Adapting biological
methods to the rapid screening of stapled
peptides. A, A cysteine crosslinking
stapling procedure allows phage display
screening of stapled peptides without the
need for uAA incorporation. Reproduced
with permission from ACS Chem. Biol.
2016, 11, 1422-1427, Copyright 2016
American Chemical Society. B, The
display of peptides incorporating
α-methyl-substituted cysteine on mRNA
allows screening of large libraries of
stapled peptides. Reproduced from Chem.
Commun. 2019, 55, 8959-8962, under
Creative Commons Licence CC-BY-NC,
published by The Royal Society of
Chemistry
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2.5 | Analysis of the primary sequences of
PDB-deposited stapled peptides
An analysis of crystallographic data for protein-bound stapled pep-
tides allows several conclusions to be drawn regarding their primary
sequences. The comparatively high content of unnatural amino acids
reflects the relatively short length of stapled-peptide sequences
(12-20 residues) that incorporate one, or sometimes two, staples
(Figure 6A). Previous analysis of protein-protein interactions found
that hotspots are enriched in tryptophan, arginine, and tyrosines
compared to the rest of the protein.[105] Positively charged amino
acid residues are over-represented in bound stapled peptides
(Figure 6B), consistent with their introduction to enhance solubility
and cell-permeability.[106-108] However, as noted by Bird et al.,[109]
an important balance must be struck between achieving cellular
uptake by stapled peptides, while avoiding membrane disruption.
Tryptophan, which seems to enhance cellular uptake through
favourable membrane interactions,[110–112] and also promotes
helicity,[113] is over-represented in stapled peptides in the PDB com-
pared to its natural abundance in proteins. Other values are consis-
tent with amino acids identified as either inducing (leucine)[114] or
breaking (glycine, proline, aspartate, threonine, glutamate)[115,116]
helicity.
3 | SECTION 2: SELECTION AND
PLACEMENT OF THE STAPLE RESIDUES
The selection and placement of the staple in stapled peptides requires
many considerations, including how to stabilise a desired secondary
structure,[118] while retaining sufficient flexibility to allow binding;
how to retain, or even enhance, biological activity through protein-
staple interactions; and how to influence the activity of the stapled
peptide by enhancing cell penetration. Typically these parameters are
explored sequentially and as for natural peptides, libraries of stapled
peptides can be constituted and scanned against the target protein
via different detection methods (PCR, ELISA, NMR HSQC).[119] For
example, Araghi et al. optimised the sequence of MS1, a native pep-
tide binding to Mcl-1, by first introducing an RCM staple which gave a
2-fold improvement in binding affinity.[120,121] A library of hundreds
of stapled peptides was then generated, which focussed on amino
acid mutations at key positions using natural and unnatural amino
F IGURE 5 Adapting computational methods to the study of stapled peptides. A, Location of fragments observed in MD simulations (orange)
shows the initial hotspots used for the design of a stapled peptide. Reproduced with permission from J. Phys. Chem. Lett. 2016, 7, 3452-3457,
under Creative Commons Licence CC-BY, further permissions should be sought from the American Chemical Society. B, MELD sampling swaps
two states: peptide A bound to the target with B in an unbound reference state (left); and peptide B bound with A in a reference state (right). The
ratio of populations in the two states relates to the free energy difference ΔGMELD. Reproduced with permission from J. Chem. Theory Comput.
2017, 13, 870-876, Copyright 2017 American Chemical Society. C, Peptide docking software, such as CABS-dock, shows that the peptide (blue)
docks in the original binding site (purple). Reproduced from Methods 2016, 93, 72-83, under Creative Commons Licence CC-BY
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acids; fluorescence-based on-bead screening was used for hit
detection.[120]
3.1 | Stabilising secondary structure
The alpha helix is a common motif in protein-protein recognition. A
survey of the Protein Data Bank conducted in 2009, suggested that
62% of protein complexes (out of 9339) present α-helical content at
their interfaces, and that less than 2% of the studied cases could be
targetable using a small molecule strategy.[122] α-Helical peptides, and
helical peptides mimetics present some of the most attractive alterna-
tive approaches for the design of biological tools and therapeutics.
Staple chemistries which favour α-helicity are ones which link residues
spaced by one or more turns of the helix (3/4 residues for one turn,
7 residues for two turns, 11 residues for 3 turns). Due to the increas-
ing popularity of this strategy, stapling chemistries that give rise to
α-helices have been extensively reviewed in recent years.[16,62,123–128]
They can be grouped into one-and two-component strategies
depending on whether the staple is formed using an external cross-
linking agent or not. One-component strategies using natural amino
acids consist mostly of lactam bridge formation, while those
employing uAAs are dominated by all-hydrocarbon staples generated
by RCM reactions between two alkene side-chains and “click” staples
generated through CuAAC reactions between azide and alkyne side-
chains, or thiol-ene reactions between thiol and alkene side-chains.
Two-component strategies tend to rely on cross-linking two natural
cysteine residues with a bifunctional linker, or on the use of double-
click reactions coupling across two azide-containing uAAs. Over 75%
of α-helical stapled peptides in the PDB have a clear “hydrophobic
moment” with one helical face enriched in hydrophobic residues and
one face enriched in hydrophilic residues (Table S2).
The introduction of a staple generally improves the therapeutic
properties of individual peptides as well as their helicity, but
increased helicity does not necessarily correlate with either an
increase in binding affinity or in cell permeability.[129–132] Sim et al.
demonstrated that a staple could change the dynamics of peptide-
protein interactions not only through constraining the conforma-
tion of the peptide but also by altering the hydration proper-
ties.[133] In their computational study of the interactions of a
stapled peptide with MDM2, they determined that a hydrophobic
staple creates a confined space between the protein and the staple
that traps waters, thus decreasing the “dewetting” barrier of the
binding event. However, there are only a very few studies in which
the effect of different staple chemistries on helicity have been
explored (e.g., de Araujo et al.,[134] Tian et al).[135], with most studies
to date based on the preferred stapling methodology of the chemist
generating the peptide. Thus, it is not yet possible to conclude
which is the “best” staple for stabilising the structure of α-helical
peptides.
While most staple chemistries have been optimised for helical
peptides, some other motifs have been explored. For example, a series
of stapled tankyrase inhibitors have been generated based upon a
published 10 amino acid sequence; the most potent stapled peptide
was shown to bind through the same key interacting residues, with a
beta-hairpin secondary structure.[101] Loops are another structural
feature that can easily be achieved by multivalent linkers by thio-
alkylation of cysteine residues as described by Brown et al.[136] and
Timmerman et al.[137] No specific residue spacing is required and loops
of different sizes can be obtained with this method; multi-functional
cysteine cross-linkers permit the formation of multiple loops. Peptides
in loop conformations display a larger and more complex contact area
with the protein, and usually, the linker interacts directly with the pro-
tein surface.[101,138]
F IGURE 6 Analysis of the primary amino acid sequences of stapled peptides targeting PPIs (Supporting Information). A, Amino acid
distribution in bound stapled peptides from 63 structures in the PDB (Table S2). B, Occurrence of amino acid residues in stapled peptides
normalized to their natural abundance in proteins[117]
BLUNTZER ET AL. 7 of 17
3.2 | Optimising biological activity
In general, the first step in optimising stapled peptides for a macromo-
lecular target is the identification of appropriate sites for the incorpo-
ration of the non-natural amino acids used to form the cross-link. This
is usually achieved by studying crystallographic, NMR or computa-
tional structural data; residues that are not involved in target recogni-
tion can be selected as potential sites for staple positioning, typically
with i,i + 3; i,i + 4; or i,i + 7 spacing depending on the staple chemistry
to be employed. Biological or computational alanine scanning is fre-
quently used to determine how to minimise the effect of introducing
a staple on the desired biological activity.[43,100,121] Residues are suc-
cessively mutated to alanine, and the residues conferring the least loss
of activity upon mutation are chosen for the placement of staple resi-
dues. The length of linker used for the stapling process may be
adjusted to match the optimum spacing identified by such scanning
methods (e.g., stapling across residues spaced at i,i + 7 rather than
i,i + 4).[43,93,105,139] Lau et al. investigated the p53/MDM2 interaction
with peptides constrained using a double click staple chemistry. Varia-
tions in the staple position and length were explored with a library of
24 peptides and a competitive fluorescence anisotropy assay to
detect peptide binding.[140] Correspondingly, Lalonde et al. scanned all
possible lactam staple positions (i,i + 4 and i,i + 7) on a series of ghrelin
peptides; testing their affinity for the growth hormone secretagogue
receptor type 1a (GHS-R1a) to determine their potential use as imag-
ing probes.[141] Examination of deposited stapled peptide sequences
in the PDB (Table S2) suggests there is no inherently preferred posi-
tion for the staple in the overall amino acid sequence.
Another design consideration is matching the hydrophobicity of
the staple to the protein interface. If the protein interface presents an
extended, open hydrophobic surface, energetically favourable con-
tacts with the staple may be possible. This situation is particularly
favourable for all-hydrocarbon staples formed through RCM. The
estrogen receptor (ER) has an extensive hydrophobic binding inter-
face, permitting hydrophobic interactions between the all-
hydrocarbon staple of stapled SRC2-BCP1 peptide with the protein
(Table 1, PDB code 5WGQ).[12] Similarly, it was shown for the non-
helical stapled bicyclic peptide Grb7-B4 binding to the Grb7-SH2 sub-
domain that interactions between the RCM staple and protein were
required for high-affinity binding (Table 1, PDB code 5EEQ).[138] How-
ever, staple-protein hydrophobic contacts have been observed in
other types of stapled peptides, for example, to staples formed using
a two-component double strain-promoted cyclisation with a
cyclodiyne cross-linker which also have a large hydrophobic contact
surface (Table 1, PDB code 5AFG).[142] In contrast, if the binding sur-
face of the protein is narrower,’ or cleft-like, the staple may be
directed towards the solvent. The binding interface of nuclear recep-
tor coactivator 1 (NCOA1) has a more restricted surface and the
hydrophobic staple of a stapled peptide derived from its binding part-
ner YL-2 directly faces the solvent (Table 1, PDB code 5Y7W).[143]
An analysis of crystal structures in the PDB (Table S2) indicates
that staples can adopt a broad range of orientations towards the pro-
tein surface or solvent (Figure 7A). The most frequent depositions
arise from the use of all hydrocarbon staples at either i,i + 4 or i,i + 7
spacing (red and blue points, Figure 7A). The surface area of the pro-
tein in contact with the stapled peptide varies from 700 Å2 to
3000 Å2, with an average value of 1550 Å2. The mean value for the
surface hydrophobicity was found to be close to zero, indicating that
stapled peptides can bind both polar and hydrophobic surfaces. The
staple angle (θ) is defined as the angle from the centre of mass of the
peptide, to two points representing the centre of mass of the protein,
and the centre of mass of the staple residues (when all three are trans-
lated into the same plane as shown in Figure 7B), and θ varies
between 40 and 180, with an average value of 103. A weak corre-
lation (R2 = 0.34) is observed between this staple angle and the hydro-
phobicity of the protein surface to which it is bound. This relatively
modest correlation is in part due to the difficulty in comparing bound
stapled peptides, where proteins wrap around the stapled peptides
differently, with one, two, or sometimes even three, interfaces with
the stapled peptide. Thus, the angle of the staple residues to the pro-
tein surface is not always directly equivalent to the angle made by the
centre of mass of the staple residues to the centre of mass of the pro-
tein used in this analysis. Nevertheless, there is a trend which indi-
cates that for all staple chemistries, the more hydrophobic the PPI
surface is, the more the staple will tend to lean towards it (low θ) and
the more polar the surface, the more the staple will be oriented away
from it (high θ). Overall this indicates that consideration of the protein
surface hydrophobicity may be a useful strategy in general, but
detailed investigation of specific binding site features remains impor-
tant to guide staple placement.
3.3 | Ranking cell penetration by staple chemistry
In their study, Lau et al. developed helical peptides with nanomolar
affinity to MDM2 using an i,i + 7 double-click stapling technique.
However, some of the most potent binders of MDM2 were found to
be inactive in a p53 reporter cellular assay due to poor uptake.[142]
Only a few studies have directly compared the effects of different
types of staple chemistry on similar sequences, therefore it is difficult
to generalise about the impact of staples on factors such as helicity,
or cell uptake.[31] Maximising helicity has been one of the principle
aims of many chemical studies, but it has been shown that flexibility
in macrocyclic structures is often critical in allowing a peptide to cross
the cellular lipid membrane.[145]
To compare the effect of staple chemistries, Araujo et al. studied
the stapling of a penta-alanine peptide and concluded that a lactam
bridge leads to the most helical peptides, followed by hydrocarbon
and triazole staples.[134] Tian et al. also concluded that for a 12-mer
peptide sequence in an aqueous solution, the highest helicity was
observed for lactam and all-hydrocarbon stapled peptides followed by
triazole stapled peptides, while the helicity of a m-xylene bridged pep-
tide was only increased by 10% over the natural sequence.[135] But
notably Tian et al. discovered that the highest cell permeability was
recorded for all-hydrocarbon and perfluorobenzene stapled peptides,
which also have the highest hydrophobicity; a result which was
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TABLE 1 Examples of stapled-peptide protein interactions
Protein-peptide interaction
PDB
Code Staple Staple interaction with protein surface
Staple
angle θa Reference
5WGQ RCM i,i + 4 and
Lactam i,i + 4
Hydrophobic interaction of all-
hydrocarbon staple with the surface;




5EEQ RCM i,i + 7 Close contacts of bis-allyl serine staple
with Met495, Asp496, Asp497
backbone, and side-chains of EF loop and
Ile 518 of BG loop
NDb 138
5AFG Bis click i,i + 7 Hydrophobic interaction of cyclodiene
staple with the surface
34 142
5Y7W RCM i,i + 4 No interaction with the protein: all-
hydrocarbon staple faces the solvent
162 143
aStaple angle θ defined in Figure 7B.
bStaple angle θ not defined for this peptide.
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consistent across four cell lines tested.[135] Muppidi et al. used a series
of aryl and vinylaryl groups to cross link i,i + 7 cysteine residues by
alkylation; they also found a correlation between cell permeability and
hydrophobicity.[146] Finally, Nielsen et al. found that while orally bio-
available cyclic peptides frequently violate the “Rule of 5” for small
molecules with a MW > 500, their lipophilicity still tends to conform,
with values in the range LogP = 0 to 5.[147]
4 | SECTION 3: ADDING FUNCTIONALITY
TO THE STAPLED PEPTIDE
Functionality may be readily added to stapled peptides through the
addition of further residues to the primary sequence. For example,
Dougherty et al. have shown that the addition of cell-penetrating pep-
tide (CPP) sequences, can be used to enhance the cellular uptake of
stapled peptides.[148] Addition of a cyclic CPP to the C-terminus of a
stapled peptide which binds MDM2, resulted in improved cytosolic
delivery and cellular EC50 values equivalent to the small molecule
inhibitor, nutlin 3a. Alternatively, the addition of E3 ligase targeting
peptide sequences to stapled peptides has been explored by Jiang
et al., in the construction of a proteolysis-targeting chimera
(PROTAC).[149] TD-PERM, a stapled peptide with proven activity
against Estrogen Receptor α (ERα), was linked to a pentapeptide
which binds the Von Hippel-Lindau (VHL) E3 ligase. The resultant het-
ero bi-functional TD-PROTAC induced degradation of ERα in a
proteasome-dependent manner inhibited the proliferation of ERα-
positive breast cancer cells and led to tumour regression in an MCF-7
mouse xenograft model.
Successful strategies for functionalising the staple component of
a stapled peptide require chemistry which is orthogonal to that of the
peptide. It is generally easier to introduce additional functionality to
staples formed using a bi-component strategy (cysteine cross-linking,
double CuAAC, etc.) than their mono-component counterparts (all-
hydrocarbon RCM, mono CuAAC, etc.). Staple functionalisation may
be used to add functional groups to track, or solubilise, the stapled
peptide (Figure 8A); to modulate the activity of the stapled peptide
(Figure 8B); or to polymerise the peptide, giving rise to multivalent
species (Figure 8C).
4.1 | Attachment of functional groups
Fluorescence is often used to follow the uptake of peptides into cell
and tissues and a range of methods have been developed to attach
fluorescent probes to peptides.[150] However, it has been shown than
the fluorescent moiety itself can induce changes in peptide
uptake.[151] Todorovic et al. have developed a one-pot stapling strat-
egy which couples a cysteine and an amine-terminated amino acid in
the presence of ortho-phthalaldehydes forming an isoindole-bridged
peptide which is inherently fluorescent (Figure 9A).[20]
Functionalisation is not limited to fluorescence, and Wu et al.,
describe a library of functionalised dialkynyl linkers compatible with
double CuAAC stapling of peptides (Figure 9B); these include linkers
with additional non-peptidic polyamines and nuclear targeting pep-
tides.[31] It was shown that in vitro binding affinity for MDM2 was not
significantly affected by the linker chemistry; but positively charged
residues enhanced both cellular uptake and target engagement in cell
reporter assays.
Two different approaches to modifying the pharmacokinetics of
stapled peptides through staple PEG-ylation have been explored. Xiao
et al. used a one-component strategy to explore the effects of PEG-
ylation on the conformational stability of the β-sheet WW domain,
using amino acids containing both PEG motifs and an alkene function
and RCM to cross-link the staple.[152] In contrast, Tian et al. used a
bis-cysteine alkylation strategy and a linker containing the PEG motif
to probe the dual agonist activity of a series of stapled peptides
against GLP-1R and GCGR (Figure 9C).[153]
F IGURE 7 Analysis of the staple angle θ for 42 protein-bound, stapled peptide structures found in the PDB (Supporting Information). A, Plot
of staple angle θ against the protein surface hydrophobicity with staple residues coloured by staple type. Surface hydrophobicity was calculated
using the solvent-accessible surface area (SASA) of each amino acid present at the binding surface, multiplied by its Eisenberg value (Table S1)[144]
divided by the total area of the binding surface. More positive values denote more hydrophobic interfaces. Staple angle θ was calculated by
translation (black arrows) of the centre of mass of the protein (blue sphere) and the centre of mass of the staple residues (yellow sphere) to the
plane defined by the vector of the helix (red/green axis) and the centre of mass of the helix (green sphere). Illustrated for PDB structure 3MK8 in
B and B1
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A large selection of chemistries have been adapted to peptides
and allow some modulation for specific added functionality. Vasco
et al. developed an Ugi reaction operating on modified side-chains can
both stabilize an α-turn and introduce N-functionalization on the
lactam bridge (Figure 9D).[154] Assem et al. reported the chemical
linking of thiol by acetone further functionalised on the ketone moiety
with diverse molecular tags by oxime ligation (Figure 9E).[155] In addi-
tion to stabilizing helical structures, this functionalisation provide
opportunities to improve both peptide-target interactions and other
peptide properties.
4.2 | Modulation of stapled peptide function
The helicity of stapled peptides can be made photoswitchable by
incorporating a photo-isomerisable group into the staple itself. UV
or visible light irradiation enables both spatial and temporal control
in investigating the effects of helicity on, for example, target
binding.[156] Brendenbeck et al. reported the first azobenzene-
based photoswitchable stapled peptide,[157] in which the central
azobenzene linker was coupled to i,i + 7 spaced cysteine residues
via two 2-iodoacetamide groups. In a related approach, Hoppmann
F IGURE 8 Adding functionality to the stapled peptide. A, Attachment of functional groups. B, Modulation of stapled peptide function.
C, Stapled peptide polymerisation
F IGURE 9 Attachment of functional groups using: A, an isoindole bridging group; B, double CuAAC stapling; C, bis-cysteine alkylation; D, an
Ugi multicomponent reaction; and E, acetone crosslinking with oxime functionalisation
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et al. developed a photoswitchable azo-benzene based click amino
acid which could be incorporated into peptide sequences and sta-
pled to a cysteine residue at the i + 4 position using thiol-ene
chemistry.[158] In an alternative approach to photoswitching, Mad-
den et al. developed a non-reversible staple which can be formed
in situ by a nitrile imine-mediated cycloaddition reaction when
peptides are irradiated at 302 nm.[33] The benzyl-pyrazole group
produced by this stapling process is fluorescent which allows it to
be tracked in cells.[159]
4.3 | Stapled peptide oligomerisation/
polymerisation
Oligomerisation/polymerisation enhances the protease resistance
of stapled peptides and provides multivalent interactions; hence
several different strategies have been reported. Tran et al. have devel-
oped a CuAAC-based polymerisation approach in which 1,3,5-
triethynylbenzene is used to staple across i,i + 7 spaced azido residues
on the peptide. This leaves a further alkyne on the staple which can
be dimerised using a bis-azido linker and a second CuACC reac-
tion.[160] In an alternative approach, Lee et al. have developed a ‘sta-
pling polymerisation’ procedure which allows the synthesis of
multimers with 3 to 16 embedded helical peptides.[161] Acryloyl
groups were added to the side-chains of lysine residues at i,i + 7 posi-
tions in the peptide sequence and free radical polymerisation was
achieved in the presence of acrylamide monomer.
5 | SECTION 4: ENHANCING
THERAPEUTIC DELIVERY
The four main routes of drug administration are oral, intravenous and
subcutaneous injection, and transdermal delivery (Figure 10). Oral and
transdermal delivery are often considered as the best routes of admin-
istration as they are painless, non-invasive and do not require trained
medical personnel.[162] Most peptide therapeutics are subject to rapid
proteolysis, which explains their generally poor pharmacokinetics;
proteases are found throughout the body, but mostly in the gastroin-
testinal (GI) tract, liver, kidneys, and blood.[128] Major contributors to
metabolism (e.g., trypsin and chymotrypsin) generally hydrolyse pep-
tide bonds between specific amino acids; thus to improve short half-
lives mutation and/or rearrangement of the primary amino acid
sequence can be performed to avoid protease-cleavage sites. Kim
et al. introduced single amino acid substitutions in GNU derivatives
and produced AMPs resistant to proteases.[163] Tools such as
Pepcutter,[164] which uses the initial sequence and a library of the
most common proteases and their associated cleavage sites to predict
the susceptibility of a peptide towards hydrolysis, can be used to opti-
mise the primary sequence. Constraining a peptide through stapling
has been shown to enhance the stability of peptides towards proteol-
ysis in several studies.[165,166] A second challenge for hydrophilic pep-
tide therapeutics is rapid renal clearance from the blood, which
prevents efficient uptake in tissues. Binding to albumin and other pro-
teins reduces renal filtration, and peptide conjugation to PEG, or a
lipophilic moiety, can also improve serum half-life. Pessi et al. pro-
duced a doubly lactam-bridged stapled peptide conjugated to choles-
terol which acts as fusion inhibitor for the Ebola virus;[167] they
reported an extended serum half-life for the cholesterol-conjugated
peptide allowing daily dosing. Finally, the amino acid sequence of a
peptide affects its propensity to aggregate, to form either amorphous
or amyloid-like fibrils; a number of programmes are now available to
predict this,[168,169] based on contributing factors such as hydropho-
bicity, charge state, and β-sheet forming propensity.[168,170,171]
5.1 | Oral delivery
Oral delivery is the most frequently employed drug delivery mode, but
it is also the most challenging for peptides (Figure 10A). Under the
acidic conditions of the GI tract (as low as pH 1.0-3.0) some amino
acids form by-products, for example cysteine, methionine and trypto-
phan are all susceptible to oxidation. Substitution of these sensitive
amino acids (e.g., norleucine for methionine, and serine for cysteine)
F IGURE 10 Barriers to the therapeutic delivery of stapled peptides. A, Peptides administered orally are subject to low pH and degradation by
proteases; B, Peptides administered intravenously appear as a high initial burst, but are subject to degradation by serum proteases. C, Peptides
administered transdermally must pass multiple layers of the epithelium
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can increase peptide stability while retaining activity. N-terminal glu-
tamine is also unstable at low pH and replacing this amino acid, or
using an acetate capping group, can prevent its cyclisation.[172,173]
Orally available peptide drugs have on average 8.7 HBA and 4.5
HBD;[174] it is thought that the highly acidic conditions of the GI
tract disrupt backbone hydrogen bonding, destabilizing helical and
beta-sheet conformations and making peptides more susceptible to
proteases. The number of rotatable bonds in a peptide is also
inversely correlated with oral bioavailability and most successful
orally available peptides marketed to date are cyclic peptides (e.g.,
cyclosporine).[175,176] In the case of stapled peptides, the improved
stability arising from side-chain cross-linking can enable absorption,
as seen with a 36-residue double-stapled peptide following oral
gavage.[177] Finally, enhanced lipophilicity can be used to increase
the half-lives of peptides; fatty acid conjugation of GLP-1 analogues
has been shown to increase their half-life from 10 to 12 hours to
days.[142]
As a second challenge, the gut epithelium is composed of multiple
layers of cells and mucus, which the peptide therapeutic must cross.
Four modes of transport are available: passive diffusion through the
cells (transcellular) and through intercellular junctions (paracellular);
by endocytosis followed by endosomal release; or by receptor-
mediated mechanisms.[178] Peptides with MW > 700 Da have only
limited paracellular permeation in intestinal epithelia,[179,180] and an
upper limit to permeation has been suggested as MW ~ 3.5 kDa by
Rubas et al.[181,182] However, Ji et al. have reported the oral absorp-
tion of a 5.3 kDa cyclotide targeting intracellular MDM2.[183] The
doses used in this study were high (40 mg/kg), and the peptide was
administered in 5% dextrose, which is known to enhance intestinal
permeability; but evidence of activity after oral administration against
this intracellular target was reported. The MW of current oral peptide
therapeutics is typically around 800 Da and does not generally
exceed 2000 Da.[174]
5.2 | Intravenous and subcutaneous injection
Intravenous or subcutaneous injections currently represent the main
delivery method for peptide therapeutics.[184] Drugs injected intrave-
nously have a high initial bioavailability (Figure 10B) as this is defined
as the proportion of a drug that is available in the bloodstream. Subcu-
taneous injection does lead to a slightly greater variability in bioavail-
ability, since peptides with a higher molecular weight have been
linked to a greater absorption by the lymphatic system rather than the
blood.[185,186] Overall, the most notable limitation of these delivery
methods is the initial “burst” encountered when the peptide is
injected, which is followed by the rapid degradation of peptide.
5.3 | Transdermal delivery
Transdermal applications include topical (skin), buccal (mouth), cor-
neal, and intranasal delivery; as for oral administration, one of the
major challenges is transport of the stapled peptide through multiple
layers of cells (Figure 10C). Enhanced cell penetration often increases
trans epithelial bioavailability.[180,187] Some transdermal drugs such as
cortisone, or anti-inflammatory drugs are limited to a local distribution
usually for skin or tissue-related conditions. However there are many
cases where application of a drug to the skin have been proven effi-
cient for systemic delivery (nicotine, oestrogen). Despite typically low
absorption, dermal administration avoids the first-pass liver metabo-
lism that occurs for oral drugs. The stratum corneum, constituting the
top layer of the skin limits the transdermal absorption of polar and
large peptides.[188,189] The lipid structure of the stratum corneum can
be disrupted by natural peptides (e.g., magainin) when these are
applied in combination with a surfactant chemical enhancer leading to
enhanced skin permeation.[189] Several hundred peptides that
enhance the skin permeability of drugs are collated in the database
TopicalPdb.[190] AMong the reported sequences, arginine and lysine
combined with lipophilic natural and unnatural amino acids are found
extensively. Chemical modifications of peptides, such as the addition
of lipophilic moieties, have also been shown to increase stability and
skin permeability.[167,191,192]
Transmucosal nasal drug delivery has also emerged as an impor-
tant field in drug delivery technology due to the high vascularity and
large surface area, which enable drug uptake.[180] Intranasal delivery
can allow the absorption of peptides of up to 2 kDa without absorp-
tion enhancers, and peptides of 2-6 kDa with absorption
enhancers.[193] Peptides can also be used as modulators to facilitate
the uptake of drugs; in general, cell penetrant peptides display excel-
lent absorption.[194] Peptide drugs on the market using intranasal
delivery include desmopressin, a cyclic peptide used to treat diabetes
insipidus. However, intranasal delivery is not appropriate for the treat-
ment of infants, for whom alternative delivery methods, such as buc-
cal delivery, must be sought.[195] Although stapled peptides have not
yet entered clinical trials using intranasal delivery, several stapled pep-
tides have shown efficacy in mouse models. Gaillard et al. reported a
double-stapled RSV peptide, which disrupts viral cell entry and signifi-
cantly decreases pulmonary infection in mice following intranasal
delivery.[43]
6 | CONCLUSIONS
This review has focused on the many considerations required for
the design of biologically active stapled peptides, drawing from the
extensive recent literature, and from analysis of PDB deposited
structures containing protein-bound stapled peptides. The growing
recognition of the utility of stapled peptides is fuelling the develop-
ment of bespoke computational tools, synthesis procedures and bio-
logical assays, that are accelerating their adoption as a research
tool. With dozens of new publications every month from research
groups across the world, and several stapled peptides entering
clinical trials, there is ample evidence that stapled peptide technolo-
gies will play an increasingly important role in pharmaceutical
applications.
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